195320-97-9

Upstream product

• 20793-64-0 (+)-(S)-2-Benzyloxy-2-methylmalonyl monoethyl ester monochloride 
• 148762-54-3 cyclo-(-Azaphenylalanyl-L-prolyl-) 
• 195320-96-8 (S)-2-Benzyloxy-2-methyl-malonic acid (S)-3-benzyl-4-oxo-3,4,6,7,8,8a-hexahydro-pyrrolo[1,2-d][1,2,4]triazin-1-yl ester ethyl ester 

Downstream Products

• 195320-98-0 (2R,8aS,8bS)-4-Benzyl-8b-hydroxy-2-methyl-3,5-dioxo-octahydro-1-oxa-3a,4,5a-triaza-as-indacene-2-carboxylic acid ethyl ester 
• 195320-99-1 (2R,8aS,8bS)-4-Benzyl-8b-hydroxy-2-methyl-3,5-dioxo-octahydro-1-oxa-3a,4,5a-triaza-as-indacene-2-carboxylic acid 
• 195321-00-7 (2R,8aS,8bS)-4-Benzyl-8b-hydroxy-2-methyl-3,5-dioxo-octahydro-1-oxa-3a,4,5a-triaza-as-indacene-2-carbonyl azide 
• 1027967-00-5 C₂₂H₂₇N₃O₈ 

Relevant academic research and scientific papers

Approaches to pseudopeptidic ergopeptines. Part 3. Consequences of the incorporation of an α-azaphenylalanine residue into the ergotamine oxa-cyclolic system

In the context of a research program aimed at synthesizing pseudopeptidic ergopeptines, the incorporation of an α-azaPhe residue into the peptidic moiety of ergotamine has been studied. Acylation of cyclo(-azaPhe-Pro-) 6 with (+)-(S)-2-benzyloxy-2-methylm